ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
5.66
-0.17 (-2.90%)
Jul 30, 2026, 10:23 AM EDT - Market open
ARS Pharmaceuticals Employees
As of March 31, 2026, ARS Pharmaceuticals had 159 total employees, including 154 full-time and 5 part-time employees. The number of employees decreased by 4 or -2.45% since the number was last reported on December 31, 2025.
Employees
159
Change
-4
Growth
-2.45%
Revenue / Employee
$622,553
Profits / Employee
-$1,245,132
Market Cap
562.13M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2026 | 159 | -4 | -2.45% | 154 | 5 |
| Dec 31, 2025 | 163 | 3 | 1.88% | 158 | 5 |
| Dec 31, 2024 | 160 | 134 | 515.38% | 155 | 5 |
| Dec 31, 2023 | 26 | 6 | 30.00% | 24 | 2 |
| Dec 31, 2022 | 20 | 11 | 122.22% | 17 | 3 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| REGENXBIO | 371 |
| 4D Molecular Therapeutics | 196 |
| CorMedix | 191 |
| Allogene Therapeutics | 152 |
| Prime Medicine | 146 |
| Silence Therapeutics | 88 |
| Zevra Therapeutics | 61 |
| Tectonic Therapeutic | 60 |
SPRY News
- 22 days ago - ARS Pharmaceuticals announces CEO succession - TheFly
- 22 days ago - ARS Pharmaceuticals Announces CEO Succession - GlobeNewsWire
- 5 weeks ago - ARS reports no new commercial formulary additions, coverage decisions for neffy - TheFly
- 5 weeks ago - ARS Pharmaceuticals Provides Commercial and Financial Updates - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals price target raised to $30 from $12 at Cantor Fitzgerald - TheFly
- 2 months ago - ARS Pharmaceuticals Earnings Call Transcript: Q1 2026 - Transcripts
- 2 months ago - ARS Pharmaceuticals Earnings release: Q1 2026 - Filings
- 2 months ago - ARS Pharmaceuticals Quarterly report: Q1 2026 - Filings